{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:10:10Z","timestamp":1773810610449,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the pharmacokinetics (PK) of linezolid in plasma and pleural fluid (PF) in critically ill patients with proven or suspected Gram-positive bacterial infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Observational PK study in 14 critically ill patients treated with linezolid at standard doses. Blood and PF samples were collected and analysed by HPLC. The ratio between PF and plasma concentrations was calculated. The PK\/pharmacodynamic (PD) target of linezolid in plasma was defined as 100% of the duration of the dosing interval in which concentrations were above the MIC (%100 T\u200a&amp;gt;\u200aMIC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median (5th and 95th percentiles) linezolid concentration values for plasma pre-dose at steady state (Cmin,ss) and at the end of the 1-h infusion at steady state (Cmax,ss) were 1.1 (0.02\u201328.3) and 13.8\u2005mg\/L (2.9\u201338.1), respectively, and the PF pre-dose concentration (PF0\u2005h) and PF concentration at the end of the 1-h intravenous infusion (PF1\u2005h) were 2.8 (0.1\u201331.6) and 4.2\u2005mg\/L (0.1\u201345.2), respectively. At both times (pre-dose and post-infusion), a strong positive correlation was observed between PF and plasma linezolid concentrations (Spearman\u2019s rho coefficients\u200a=\u200a0.8 and 0.9, with P\u200a&amp;lt;\u200a0.001 for both). The defined PK\/PD target in plasma was achieved in 8 (57.1%), 4 (28.6%) and 3 (21.4%) patients assuming an MIC of 1, 2 and 4\u2005mg\/L, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Linezolid seems to penetrate well into the PF, with concentrations exceeding those in plasma. However, high inter-individual variability, both in plasma and PF concentrations, was observed. A high proportion of patients did not achieve the PK\/PD target in plasma, especially in the presence of high MIC strains.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae444","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T11:22:51Z","timestamp":1735212171000},"page":"554-562","source":"Crossref","is-referenced-by-count":2,"title":["Penetration of linezolid into the pleural cavity in critically ill patients with proven or suspected Gram-positive bacterial infections: a retrospective pharmacokinetic study"],"prefix":"10.1093","volume":"80","author":[{"given":"Marta","family":"De Antonio-Cusc\u00f3","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital del Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Sorl\u00ed","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department , Hospital del Mar, Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d' Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosana","family":"Mu\u00f1oz-Berm\u00fadez","sequence":"additional","affiliation":[{"name":"Critical Care Department, Hospital del Mar , Hospital del Mar ,","place":["Spain"]},{"name":"Critical Illness Research Group (GREPAC), Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"L\u00f3pez-Mula","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Can Misses , Ibiza ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Jos\u00e9","family":"Parrilla","sequence":"additional","affiliation":[{"name":"Critical Care Department, Hospital del Mar , Hospital del Mar ,","place":["Spain"]},{"name":"Critical Illness Research Group (GREPAC), Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pilar","family":"Gracia-Arnillas","sequence":"additional","affiliation":[{"name":"Critical Care Department, Hospital del Mar , Hospital del Mar ,","place":["Spain"]},{"name":"Critical Illness Research Group (GREPAC), Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Prim","sequence":"additional","affiliation":[{"name":"Laboratori de Refer\u00e8ncia de Catalunya, Department of Microbiology , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Campillo Ambr\u00f3s","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P","family":"Horcajada","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department , Hospital del Mar, Barcelona ,","place":["Spain"]},{"name":"Laboratori de Refer\u00e8ncia de Catalunya, Department of Microbiology , Barcelona ,","place":["Spain"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d' Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan Ramon","family":"Masclans-Enviz","sequence":"additional","affiliation":[{"name":"Critical Care Department, Hospital del Mar , Hospital del Mar ,","place":["Spain"]},{"name":"Critical Illness Research Group (GREPAC), Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar , Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d' Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f2nia","family":"Luque","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar , Barcelona ,","place":["Spain"]},{"name":"CIBERINFEC, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d' Investigacions M\u00e8diques (IMIM) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"2025020223513732600_dkae444-B1","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.21037\/jtd-2021-31","article-title":"Management of complex pleural disease in the critically ill patient","volume":"13","author":"Hu","year":"2021","journal-title":"J Thorac Dis"},{"key":"2025020223513732600_dkae444-B2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.chest.2016.09.032","article-title":"Pleural infections in intensive care","volume":"150","author":"Fysh","year":"2016","journal-title":"Chest"},{"key":"2025020223513732600_dkae444-B3","first-page":"1129","article-title":"Linezolid","volume":"41","author":"Narang","year":"2004","journal-title":"Indian Pediatr"},{"key":"2025020223513732600_dkae444-B4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1185\/03007990903512057","article-title":"The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus\u202f: vancomycin and linezolid","volume":"26","author":"Stein","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2025020223513732600_dkae444-B5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ijantimicag.2014.07.001","article-title":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","volume":"44","author":"Luque","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223513732600_dkae444-B6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1128\/AAC.45.6.1843-1846.2001","article-title":"Pharmacokinetics and tissue penetration of linezolid following multiple oral doses","volume":"45","author":"Gee","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513732600_dkae444-B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-9255-7-22","article-title":"Pharmacokinetics of linezolid and ertapenem in experimental parapneumonic pleural effusion","volume":"7","author":"Saroglou","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"2025020223513732600_dkae444-B8","doi-asserted-by":"publisher","first-page":"e1060-1","DOI":"10.1016\/j.ijid.2013.03.008","article-title":"Pharmacokinetics of linezolid in the mediastinum and pleural space","volume":"17","author":"Tsuji","year":"2013","journal-title":"Int J Infect Dis"},{"key":"2025020223513732600_dkae444-B9","article-title":"Linezolid penetrates in human pleural cavity: a pilot study using ultra-high pressure liquid chromatography in tandem with mass spectrometry (UPLC-MS\/MS)","volume":"44","author":"Lykouras","year":"2014","journal-title":"Eur Respir J"},{"key":"2025020223513732600_dkae444-B10","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513732600_dkae444-B11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF00273563","article-title":"Validation of a severity of illness score (APACHE II) in a surgical intensive care unit","volume":"15","author":"Giangiuliani","year":"1989","journal-title":"Intensive Care Med"},{"key":"2025020223513732600_dkae444-B12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2025020223513732600_dkae444-B13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/0003-4819-77-4-507","article-title":"Pleural effusions: the diagnostic separation of transudates and exudates","volume":"77","author":"Light","year":"1972","journal-title":"Ann Intern Med"},{"key":"2025020223513732600_dkae444-B14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/jac\/dku337","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation","volume":"70","author":"Cojutti","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513732600_dkae444-B15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jac\/45.3.329","article-title":"High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures","volume":"45","author":"Pea","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513732600_dkae444-B16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025020223513732600_dkae444-B17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet (London, England)"},{"key":"2025020223513732600_dkae444-B18","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","article-title":". Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"2025020223513732600_dkae444-B19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223513732600_dkae444-B20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2025020223513732600_dkae444-B21","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/cid\/ciz093","article-title":"Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired\/ventilator-associated bacterial pneumonia clinical trials","volume":"69","author":"Weiss","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025020223513732600_dkae444-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-020-2763-4","article-title":"Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial","volume":"24","author":"Ben\u00edtez-Cano","year":"2020","journal-title":"Crit Care"},{"key":"2025020223513732600_dkae444-B23","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513732600_dkae444-B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jss.2008.03.040","article-title":"Comparison of the therapeutic efficacy of linezolid and vancomycin and correlation of serum and tissue malondialdehyde and myeloperoxidase in an experimental mediastinitis model","volume":"152","author":"Sacar","year":"2009","journal-title":"J Surg Res"},{"key":"2025020223513732600_dkae444-B25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513732600_dkae444-B26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"2025020223513732600_dkae444-B27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.envint.2015.10.015","article-title":"Concentrations of antibiotics predicted to select for resistant bacteria: proposed limits for environmental regulation","volume":"86","author":"Bengtsson-Palme","year":"2016","journal-title":"Environ Int"},{"key":"2025020223513732600_dkae444-B28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1751143714564816","article-title":"Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient","volume":"16","author":"Shah","year":"2015","journal-title":"J Intensive Care Soc"},{"key":"2025020223513732600_dkae444-B29","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2147\/IDR.S357300","article-title":"Plasma and intrapulmonary pharmacokinetics, and dosage regimen optimization of linezolid for treatment of Gram-positive cocci infections in patients with pulmonary infection after cerebral hemorrhage","volume":"15","author":"Wei","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2025020223513732600_dkae444-B30","doi-asserted-by":"publisher","first-page":"559671","DOI":"10.3389\/fmed.2020.559671","article-title":"Endotoxemia-induced release of pro-inflammatory mediators are associated with increased glomerular filtration rate in humans in vivo","volume":"7","author":"Beunders","year":"2020","journal-title":"Front Med"},{"key":"2025020223513732600_dkae444-B31","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1128\/AAC.01694-12","article-title":"Risk factors for a low linezolid trough plasma concentration in acute infections","volume":"57","author":"Morata","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223513732600_dkae444-B32","doi-asserted-by":"publisher","first-page":"479730","DOI":"10.1155\/2013\/479730","article-title":"Epidemiology of acute kidney injury in the intensive care unit","volume":"2013","author":"Case","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"2025020223513732600_dkae444-B33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/FTD.0000000000000665","article-title":"Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity","volume":"41","author":"Luque","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2025020223513732600_dkae444-B34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/jac\/dkv349","article-title":"Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513732600_dkae444-B35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/antibiotics11040436","article-title":"Linezolid administration to critically ill patients: intermittent or continuous infusion? A systematic literature search and review","volume":"11","author":"Jullien","year":"2022","journal-title":"Antibiot"},{"key":"2025020223513732600_dkae444-B36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00134-014-3550-y","article-title":"Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration","volume":"41","author":"De Pascale","year":"2015","journal-title":"Pharmacokinet Intensive Care Med"},{"key":"2025020223513732600_dkae444-B37","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/jac\/dks022","article-title":"Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia","volume":"67","author":"Boselli","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025020223513732600_dkae444-B38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1515\/jccm-2016-0017","article-title":"Anemia in intensive care: a review of current concepts","volume":"2","author":"Rawal","year":"2016","journal-title":"J Crit Care Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/554\/61276792\/dkae444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/554\/61276792\/dkae444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T23:51:45Z","timestamp":1738540305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/2\/554\/7932790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,26]]},"published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae444","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,26]]}}}